The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims to provide an assay to aid research on infections caused by Pseudomonas aeruginosa, delivering a solution to accelerate wound care research and reduce the reliance on mammalian testing. The project focuses on developing an industrial whole organism assay for biofilms […]
Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Michael Fasseas (left) Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services provider in using the nematode worm C. elegans to accelerate drug discovery and other research in the areas of the gut microbiome, ageing, and neurodegeneration, […]
Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-the-key-to-slowing-ageing/ Health Tech World spoke to Magnitude Biosciences about its groundbreaking work with C. elegans and how it is assisting biotechs in the development of drugs that can slow ageing and tackle age-related neurodegenerative diseases. C. elegans is a tiny worm about a millimetre in length. It’s been used in research since […]
How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "The Future of Longevity II"
Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the industrial drug discovery process
Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 2021 by ELRIG and the British Pharmacological Society
